Abstract
Introduction
Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC).
Materials and methods
We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1–5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS.
Results
51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p < 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1–2 toxicity and 2 cases of acute G3 biliary obstruction.
Conclusions
Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.
Similar content being viewed by others
References
Abou-Alfa GK, Macarulla Mercade T, Javle M et al (2019) ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation [abstract LBA10_PR]. ESMO 30:v872–v873
Andratschke N, Alheid H, Allgäuer M et al (2018) The sbrt database initiative of the German society for radiation oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283
Barney BM, Olivier KR, Miller RC, Haddock MG (2012) Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7:67
Bergquist A, Von SE, Physician R (2015) Best practice & research clinical gastroenterology epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 29:221–232
Correa RJM, Salama JK, Milano MT, Palma DA et al (2016) Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J 22(4):247–256
Franzese C, Franceschini D, Cozzi L et al (2017) Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Res Treat 49(1):20–28
Franzese C, Zucali PA, Di Brina L et al (2018) The efficacy of stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med 7(9):4379–4386
Glimelius B, Hoffman K, Sjoden P-O, Jacobsson G, Sellstrom H, Enander L-K et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600. https://doi.org/10.1093/oxfordjournals.annonc.a010676
Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0
Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 31:1256–1263. https://doi.org/10.1007/s00268-007-9001-y
Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689–1700. https://doi.org/10.1002/cncr.11699
Jung DH, Kim MS, Cho CK et al (2014) Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 32:163–169
Klement RJ, Hoerner-Rieber J, Adebahr S et al (2018) Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol 127(2):246–252
Lamarca A, Palmer DH, Wasan HS et al (2019) ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol 37(15_suppl):4003–4003
Lee J, Yoon WS, Koom WS et al (2019) Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 195(2):93–102
Morino K, Seo S, Yoh T et al (2020) Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol 27(6):1908–1917
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5
Sawyer CD, Minnis JF (1956) Primary carcinoma of the gallbladder. Am J Surg 91:99–105. https://doi.org/10.1016/0002-9610(56)90142-8
Sebastian NT, Tan Y, Miller ED, Williams TM, Noonan AM, Hays JL et al (2019) Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma. JAMA Netw Open 2:e1911154. https://doi.org/10.1001/jamanetworkopen.2019.11154
Silva VWK, Askan G, Daniel TD et al (2016) Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 5:62
Tagawa T, Ito K, Fukuzawa K et al (2017) Surgical resection for pulmonary metastasis from pancreatic and biliary tract cancer. Anticancer Res 37:1413–1416
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721
Valle JW, Lamarca A, Goyal L et al (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7(9):943–962. https://doi.org/10.1158/2159-8290.CD-17-0245
Wainberg ZA, Lassen UN, Elez E, Italiano A, Curigliano G, De Braud FG et al (2019) Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J Clin Oncol 37:187–187
Wilke L, Andratschke NBO et al (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlentherapie Und Onkol 195:193–198
Yamaguchi K, Chijiiwa K, Ichimiya H, Sada M, Kawakami K, Nishikata F et al (1996) Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch Surg 131:981–985. https://doi.org/10.1001/archsurg.1996.01430210079015
Funding
No funding was used for the present work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no conflict of interest disclosures from any authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Franzese, C., Bonu, M.L., Comito, T. et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol 146, 2289–2297 (2020). https://doi.org/10.1007/s00432-020-03285-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03285-9